Neurotech Reports Positive Top-Line Phase I/II Rett Syndrome Clinical Trial Results Key Points:
• NTIRTT1 is the first clinical trial to show a statistically significant clinical improvement in Rett Syndrome patients (n=14) with a broad-spectrum cannabinoid drug therapy (NTI164)
• Primary endpoint of Clinical Global Impression – Improvement (CGI-I) at 12 weeks versus baseline was met; mean improvement of -0.3, (p=0.04)
• CGI-I compares favourably to the only FDA approved Rett Syndrome drug DAYBUE™ (trofinetide) Phase 3 CGI-I data vs placebo in Rett -0.3, 8% improvement (p=0.003)
https://www.investi.com.au/api/announcements/nti/6b645e01-525.pdf
- Forums
- ASX - By Stock
- Ann: Positive Top-Line Rett Syndrome Clinical Trial Results
Neurotech Reports Positive Top-Line Phase I/II Rett Syndrome...
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.3¢ |
Change
-0.002(2.67%) |
Mkt cap ! $75.28M |
Open | High | Low | Value | Volume |
7.6¢ | 7.7¢ | 7.3¢ | $50.23K | 673.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 213825 | 7.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 105682 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 213825 | 0.073 |
7 | 1363942 | 0.072 |
3 | 996550 | 0.071 |
3 | 221284 | 0.070 |
2 | 50736 | 0.069 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 105682 | 2 |
0.076 | 181960 | 3 |
0.077 | 50000 | 1 |
0.078 | 227880 | 2 |
0.079 | 451112 | 1 |
Last trade - 12.41pm 08/05/2024 (20 minute delay) ? |
|
|||||
Last
7.3¢ |
  |
Change
-0.002 ( 2.67 %) |
|||
Open | High | Low | Volume | ||
7.5¢ | 7.7¢ | 7.3¢ | 361856 | ||
Last updated 13.16pm 08/05/2024 ? |
Featured News
NTI (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online